Objective To analyze the clinical features, prognostic factors and treatment outcomes of myeloid sarcoma (MS).
Methods We analyzed retrospectively the clinical data and prognosis of 10 patients diagnosed as MS in the Department of Hematology in Peking University Third Hospital from 2001 to 2014.
Results The median age of onset was 40.5 years, 6 female and 4 male patients. Affected areas included skin, breast, lymph nodes, parasternal area, cervix uteri, bronchus. All patients received chemotherapy and five patients were dead. Median survival was 12 months. The longest survival from diagnosis was 240 months.
Conclusion Myeloid sarcoma (MS) is a rarely local tumor. Systemic chemotherapy should be used as soon as the diagnosis is confirmed. Hematopoietic stem cell transplantation can improve the poor prognosis.